Nxera Pharma Co Ltd - Company Profile
Powered by 
All the data and insights you need on Nxera Pharma Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Nxera Pharma Co Ltd Strategy Report
- Understand Nxera Pharma Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Nxera Pharma Co Ltd (Nxera Pharma), formerly Sosei Group Corp, is a biopharmaceutical company that develops drugs by using a proprietary G protein-coupled receptor (GPCR) targeted StaR technology and structure-based drug discovery (SBDD) platform. Its medical products include ultibro, seebri, enerzair, breezhaler, pivlaz and oravi. The company's in-house pipeline programs include H4 antagonist, EP4 antagonist, SARS-CoV-2 MPro, GPR52 agonist and PAR2 mAb. Nxera Pharma partnered pipeline program comprises CCR6 antagonist, muscarinic M4 agonist, MC4 antagonist, muscarinic M1 agonist, dual muscarinic M1 and M4 agonists, GPR35 agonist, CXCR4 mAb, PAR2 peptide, targeted GPCR degradation, ion channels, OX2 agonist and mGlu5 NAM, among others. The company operates in Japan, South Korea, Ireland and the UK. Nxera Pharma is headquartered in Chiyoda-ku, Tokyo, Japan.
Headquarters
Japan
Address
Midtown East, 9-7-2, Akasaka, Minato-Ku, Tokyo, 107-0052
Website
investors.nxera.life
Telephone
81 3 52103290
No of Employees
350
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4565 (TYO)
Revenue (2022)
$94.3M
-18%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-1983%
(2022 vs 2021)
Market Cap*
$881.8M
Net Profit Margin (2022)
XYZ
-2,399.6%
(2022 vs 2021)
* As of and is in US$
Nxera Pharma Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Medicines: | StaR |
| Ultibro: Chronic Obstructive Pulmonary Disease | Sosei Heptares |
| Pivlaz: Cerebral Vasospasm | Ultibro |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In April, the company partnered with the World Orphan Drug Alliance to provide access to treatments for rare diseases and specialty medicines in complex markets across the world. |
| 2024 | Corporate Changes/Expansions | In April, the company changed its name to Nxera Pharma Co., Ltd. |
| 2024 | Regulatory Approval | In March, the company announced that Formosa Pharmaceuticals, Inc. received approval from the US Food & Drug Administration for clobetasol propionate ophthalmic suspension 0.05% (APP13007), for the treatment of post-operative inflammation and pain following ocular surgery. |
Competitor Comparison
| Key Parameters | Nxera Pharma Co Ltd | Mitsubishi Tanabe Pharma Corp | ASKA Pharmaceutical Holdings Co Ltd | Torii Pharmaceutical Co Ltd | Fuso Pharmaceutical Industries Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Minato-Ku | Osaka | Minato-Ku | Chuo-Ku | Osaka-Shi |
| State/Province | Tokyo | Osaka | Tokyo | Tokyo | Osaka |
| No. of Employees | 350 | 6,697 | 747 | 583 | 1,314 |
| Entity Type | Public | Private | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Shinichi Tamura | Chairman | Executive Board | 2016 | - |
| Chris Cargill | President; Executive Officer; Director; Chief Executive Officer | Executive Board | 2022 | - |
| Hironoshin Nomura | Chief Financial Officer; Executive Officer; Executive Vice President | Senior Management | 2022 | - |
| Toshihiro Maeda | Chief Operating Officer | Senior Management | 2024 | - |
| Kieran Johnson | Executive Officer; Chief Accounting Officer; Executive Vice President | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward